FDA adds heart warning to Pfizer anti-smoking pill

Jun 16, 2011 By MATTHEW PERRONE , AP Health Writer

(AP) -- Federal health regulators are warning doctors and patients that Pfizer's anti-smoking drug Chantix may slightly increase the risk of heart attack and other cardiovascular problems.

The said Thursday a study of 700-heart disease patients taking Chantix showed a small uptick in heart problems among those taking the drug versus those taking placebo. The agency stressed that the drug helped patients quit smoking and that this benefit "should be weighed against its potential risks when deciding to use the drug in smokers with cardiovascular disease."

Chantix is a twice-daily tablet that works by binding to nicotine receptors in the brain, reducing the symptoms of withdrawal.

The FDA will add new warnings to the drug's label about the study's findings. Patients will also receive an updated medication guide with their Chantix prescription that talks about the heart risks.

Drugmaker Pfizer will be required to analyze a large group of studies to further define the heart risk, according to the FDA. The company said in a statement that "the overall rates reported in the study were low."

Approved in May 2006, Chantix has been used by millions of patients in the U.S., though sales have declined since 2008 when the drug was first linked to psychological side effects, including depression and suicidal thoughts. It currently carries a boxed warning, the most serious type, about those risks. GlaxoSmithKline's competing drug, Zyban, carries the same warning.

New York-based . reported sales of $755 million for Chantix last year. Most of the drug's new sales have been driven by patients outside the U.S. Company shares dipped 5 cents to $20.14 in afternoon trading.

Explore further: Type 2 diabetes: Added benefit of canagliflozin plus metformin is not proven

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA: New warning needed for Chantix

Feb 03, 2008

The U.S. Food and Drug Administration Friday called for increased awareness of the health risks of the smoking cessation drug varenicline.

FDA requires Chantix, Zyban to have warning

Jul 01, 2009

(AP) -- The Food and Drug Administration will require two smoking-cessation drugs, Chantix and Zyban, to carry the agency's strongest safety warning over side effects including depression and suicidal thoughts.

FDA clears Eli Lilly's blood thinner Effient

Jul 10, 2009

(AP) -- The Food and Drug Administration on Friday approved a highly anticipated blood thinner from Eli Lilly, though the drug must carry the agency's sternest warning because of its bleeding risks.

Recommended for you

US approves new, hard-to-abuse hydrocodone pill (Update)

23 hours ago

U.S. government health regulators on Thursday approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking ...

Soaring generic drug prices draw Senate scrutiny

Nov 20, 2014

Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington ...

Only half of patients take their medications as prescribed

Nov 20, 2014

The cost of patients not taking their medications as prescribed can be substantial in terms of their health. Although a large amount of research evidence has tried to address this problem, there are no well-established ...

Interpol call for roadmap to tackle fake drugs

Nov 19, 2014

Interpol on Wednesday called for a greater global response to pharmaceutical crime as it warned criminal gangs were capitalising on weaknesses in legislation and border controls.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.